Valuation: Spyre Therapeutics, Inc.

Market Cap 7.85B 6.97B 6.52B 5.94B 11.19B 756B 11.34B 78.88B 30.54B 385B 29.47B 28.83B 1,236B P/E 2026 *
-30.6x
P/E 2027 * -24.4x
Enterprise Value 7.3B 6.48B 6.06B 5.53B 10.4B 703B 10.55B 73.35B 28.4B 358B 27.41B 26.81B 1,150B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.4%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
1 week+5.72%
Current month+3.41%
1 month+4.03%
3 months+3.58%
6 months+88.28%
Current year+181.04%
1 week 83.26
Extreme 83.255
95.08
1 month 82.93
Extreme 82.93
95.19
Current year 28
Extreme 28
110.18
1 year 15.86
Extreme 15.86
110.18
3 years 8.43
Extreme 8.43
110.18
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 26/11/2023
Director of Finance/CFO 49 31/08/2023
Chief Tech/Sci/R&D Officer - 26/11/2023
Director TitleAgeSince
Director/Board Member 36 26/11/2023
Director/Board Member 40 21/06/2023
Director/Board Member 36 21/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Chief Financial Officer

-18,232 0.0210%
02/09/26 Exercice

General Counsel

1,200 0.0014%
01/09/26 Sell

Chief Executive Officer

-15,000 0.0173%
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%+5.72%+459.36%+686.92% 7.85B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.59%-4.77%+28.52%+35.09% 44.25B
+1.05%+3.80%+352.35%+692.70% 43.99B
-1.46%+0.23%+7.65%+102.12% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.32%-9.01%-24.91%+335.93% 24.93B
Average +0.63%+1.87%+95.24%+213.45% 40.47B
Weighted average by Cap. +0.52%+1.81%+66.79%+162.33%

Financials

2026 *2027 *
Net sales - -
Net income -261M -232M -217M -197M -372M -25.11B -377M -2.62B -1.01B -12.79B -979M -958M -41.07B -342M -304M -284M -259M -487M -32.9B -494M -3.43B -1.33B -16.76B -1.28B -1.26B -53.82B
Net Debt -550M -489M -457M -416M -784M -52.96B -795M -5.53B -2.14B -26.97B -2.07B -2.02B -86.64B -567M -503M -471M -429M -807M -54.56B -819M -5.69B -2.2B -27.78B -2.13B -2.08B -89.24B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
125
Date Price Change Volume
01/10/26 US$92.00 +3.34% 902,338
30/09/26 US$89.03 +5.09% 2,096,144
29/09/26 US$84.72 -1.25% 1,053,253
28/09/26 US$85.79 +0.12% 1,045,535
25/09/26 US$85.69 -1.61% 560,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
89.03USD
Average target price
119.57USD
Spread / Average Target
+34.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock